- LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight against cancer.
- LIXTE develops LB-100, a drug that enhances the effectiveness of cancer treatments, while Liora has developed a unique cancer treatment that’s believed to be more affordable, precise, and efficient than many traditional options.
- Together, this pair of products have incredible clinical and commercial potential, to both help the businesses succeed, while also offering better outcomes for patients suffering from cancer.
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined, have the potential to improve outcomes and results for cancer patients.
LIXTE’s flagship product and lead clinical candidate is LB-100, which is a proprietary small-molecule inhibitor of protein phosphatase 2A (“PP2A”). Designed to enhance the activity of chemotherapy and immunotherapy, the compound has developed a favorable safety profile in Phase 1 clinical trials and…
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN